VHH antibodies, derived from Camelids (Camels, Llamas, Alpacas) and Sharks, consist solely of a single heavy-chain antibody variable domain. They represent the smallest known functional antibodies capable of binding (12-15 kDa). VHH Antibodies offer distinct advantages including small size, high solubility, exceptional stability, strong acid resistance, low immunogenicity, rapid blood clearance, and superior tissue penetration. Leveraging these properties, VHH Antibodies find wide applications in affinity capture, biosensing, molecular imaging, and disease diagnosis and therapy. Typically sourced from Immune or Naive Libraries, highly specific VHH antibodies are isolated using Phage Display and Screening technologies. VHH Antibodies are readily amenable to large-scale production in E. coli and possess unique antigen-binding characteristics compared to other Recombinant Antibodies.

KMD Bioscience integrates mature Phage Display and Screening technologies with our Antibody Expression and Purification Platform. This enables the rapid production of substantial quantities of VHH Antibodies tailored to client needs. Our prepared VHH Antibodies retain the full antigen-binding capacity of traditional antibodies. As of now, we have successfully generated a large number of high-affinity and specific VHH Antibodies targeting diverse antigens, including cytokines, cell surface receptors, tumor antigens, viruses, bacteria, enzymes, and toxins.

KMD customizes personalized Antibody Characterization and Functional Validation Schemes to ensure the effectiveness of the prepared VHH Antibodies. We are committed to producing high-quality Recombinant Antibodies. Utilizing Phage Display, Screening, Expression, and Purification technologies, we prepare VHH Antibodies that specifically bind their target antigens with the correct epitope.

Employing unvalidated or inadequately validated antibodies can lead to serious consequences and hinder scientific research. To guarantee the effectiveness of our Recombinant Antibodies, we subject prepared VHH Antibodies to rigorous validation. This ensures specific antigen recognition without cross-reactivity with other molecules, while guaranteeing data transparency and reproducibility. During VHH Antibody Preparation, we can design various Functional Validation Schemes based on client requirements. We provide authentic experimental data to confirm the effectiveness of the antibodies delivered. The goal of our VHH Antibody Validation is to assess specificity, sensitivity, and reproducibility against the intended target antigen, ensuring antibody reliability and enhancing the accuracy of experimental results.

We utilize common Immunological Techniques to validate prepared VHH Antibodies, confirming strong affinity and specificity. We also perform Antibody Evaluation and Optimize Experimental Parameters to ensure result credibility. KMD Bioscience employs techniques including Western Blot (WB), Immunohistochemistry (IHC), Immunocytochemistry (ICC), Immunofluorescence (IF), Enzyme-Linked Immunosorbent Assay (ELISA), Immunoprecipitation (IP), Chromatin Immunoprecipitation (ChIP), Peptide Array, Flow Cytometry (FC), and Gene Knockout Cell Lines. These methods validate antibody reproducibility, specificity, stability, and affinity, guaranteeing that our VHH Antibodies meet client requirements.

We confirm VHH Antibody specificity via WB, ensuring a single band at the expected size. Using IHC, we visualize protein expression in tissue samples by staining and localizing targets on tissue sections, verifying specific binding within tissues. We also employ techniques like RNA interference (RNAi) or CRISPR/Cas9-mediated gene knockout to silence or eliminate target proteins, ensuring VHH Antibody specificity for the intended target. Furthermore, we offer services such as Cell Proliferation or Invasion Assays to guarantee in vivo antibody efficacy.